Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial

(2021) J. Braverman et al.   VALUE IN HEALTH

Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.

(2020) Sundar Jagannath et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Patient-Reported Outcomes to Understand & Measure the Patient Experience of Novel Cell and Gene Therapies

(2020) Laura Lasiter et al.   Therapeutic Innovation & Regulatory Science

REAL-WORLD EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA FROM GERMANY

(2020) Monika Engelhardt et al.   Clinical Lymphoma Myeloma & Leukemia

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy: Qualitative analyses of pretreatment patient interviews in the KarMMa trial.

(2020) Julia Braverman et al.   JOURNAL OF CLINICAL ONCOLOGY

PCN324 Patient Reported Outcomes Among Kte-X19 CAR T Treated Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

(2020) M. José Kersten et al.   VALUE IN HEALTH

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

(2019) Philippe Moreau et al.   LEUKEMIA

Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients

(2019) Kate Sully et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

(2019) Julia Ruark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment Options for Triple-class Refractory Multiple Myeloma

(2019) Joseph Mikhael   Clinical Lymphoma Myeloma & Leukemia

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

(2019) Theodore W Laetsch et al.   LANCET ONCOLOGY

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial

(2018) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France

(2018) Nicolas Despiégel et al.   Clinical Lymphoma Myeloma & Leukemia

Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities

(2018) Rajshekhar Chakraborty et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States

(2018) S. Nolte et al.   EUROPEAN JOURNAL OF CANCER

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

(2016) G. V. Long et al.   ANNALS OF ONCOLOGY

Multiple Myeloma: Diagnosis and Treatment

(2016) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review

(2016) Rebecca Mercieca-Bebber et al.   BMJ Open

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

(2014) K. W. Song et al.   HAEMATOLOGICA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

(2013) Karin Jordan et al.   SUPPORTIVE CARE IN CANCER

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey

(2012) S. Acaster et al.   SUPPORTIVE CARE IN CANCER

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

(2012) Ben van Hout et al.   VALUE IN HEALTH

Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma

(2011) Ann Kristin Kvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Health related quality of life in a nationally representative sample of haematological patients

(2009) Anna T. Johnsen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY